Cardiovascular effects of cancer drugs: Review
Küçük Resim Yok
Tarih
2014
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Turkiye Klinikleri
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Widening the array of active antineoplastic agents has resulted in a prolongation of lifespan of cancer patients, but also increased the possibility of manifestation of adverse effects of anticancer treatment. Cardiovascular toxicity is a potential short- or long-term complication of anticancer therapy. The mechanisms of particular cardiovascular toxicities in cancer patients may differ from those of general population and the presence of cancer may limit the therapeutic options. Therefore, general treatment guidelines in cardiovascular disorders may not be appropriate in cancer patients. Additionally, cardiovascular toxicities reported in clinical trials do not always reflect those of "real world" patients. More research is needed to assess and manage the cardiovascular safety of patients treated with anticancer agents, beginning with a dynamic partnership between oncologists and cardiologists and the development of a new generation of "cardiooncologic" investigators. Cardiac toxicity associated with cancer therapies can range from asymptomatic subclinical abnormalities, including electrocardiographic changes and temporary left ventricular ejection fraction decline, to life-threatening events such as heart failure or acute coronary syndromes. The aim of this review is to summarize potential cardiovascular toxicities for a range of cancer chemotherapeutics. Given the rate of new drug development designed to fulfill unmet oncologic needs, efforts are needed to promote strategies for cardiac risk detection and management and to avoid unintended consequences potentially impeding development of, regulatory approval for, manage the cardiovascular safety of patients treated with anticancer agents, as well as a well-organized collaboration between oncologists and cardiologists. Copyright © 2014 by Türkiye Klinikleri.
Açıklama
Anahtar Kelimeler
Angiogenesis inhibitors, Antineoplastic agents, Drug toxicity, Risk factors
Kaynak
Turkiye Klinikleri Cardiovascular Sciences
WoS Q Değeri
Scopus Q Değeri
Q4
Cilt
26
Sayı
1
